Valerio Therapeutics (FRA:C4X) Forward PE Ratio : 0.00 (As of Jun. 20, 2024)

View and export this data going back to . Start your Free Trial

What is Valerio Therapeutics Forward PE Ratio?

Valerio Therapeutics's Forward PE Ratio for today is 0.00.

Valerio Therapeutics's PE Ratio without NRI for today is 0.00.

Valerio Therapeutics's PE Ratio for today is 0.00.

Valerio Therapeutics Forward PE Ratio Historical Data

The historical data trend for Valerio Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics Forward PE Ratio Chart

Valerio Therapeutics Annual Data

Trend

2016-08

Forward PE Ratio

6.54

Valerio Therapeutics Semi-Annual Data
	2016-06
Forward PE Ratio	5.00

Competitive Comparison of Valerio Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Valerio Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valerio Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's Forward PE Ratio falls into.

Valerio Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Valerio Therapeutics (FRA:C4X) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Valerio Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics (FRA:C4X) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (FRA:C4X) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

ALVIO:France

Address

49 Boulevard du General, Martial Valin, Paris, FRA, 75015

Website

https://www.valeriotx.com

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (FRA:C4X) Headlines

No Headlines